U.S. Residents

The Scientific Intake website is not intended for a U.S. audience. The website describes our product, Sensor Monitored Alimentary Restriction Therapy (SmartByte™). The product has not been cleared for marketing by the Food and Drug Administration and is not available for sale in the U.S.

SmartByte™ is limited by U.S. law to investigational use only. It has been designated Non Significant Risk by the FDA.

Outside the U.S., Scientific Intake's SmartByte™ is designated a Class I medical device and has been granted the CE Mark (Europe), and has been approved by Health Canada, Anvisa ( Brazil) and TGA (Australia).

I Understand

Clinical Research

Contact Us

A large and growing body of scientific research links rapid eating with overweight and obesity in many cases.  Over the past seven years, a great deal of academic and IRB approved clinical research has been conducted on Sensor Monitored Alimentary Restriction Therapy (SmartByte™) to validate the clinical effectiveness and safety of our device.  As part of this process, Scientific Intake has developed relationships with thought leaders around the world, including at Harvard, Yale, Lenox Hill Hospital, Monash University Medical School Australia, Imperial College of London and the prestigious Pennington Biomedical Center at LSU to incorporate their expertise into the development of SmartByte™.  In addition to those studies summarized here, there are other studies that support the link between eating rate and controlling weight.

As members of TOS (The Obesity Society), we are proud to note that research on SmartByte ™ and how rapid eating leads to obesity has been published in the journal, Obesity and presented, after peer review, at the TOS Annual Meeting.

A few highlights of the findings on Sensor Monitored Alimentary Restriction Therapy:

• SmartByte™ users reduced their daily food intake by 23%.
• SmartByte™ subjects consumed 533 fewer calories over the course of a day.
• SmartByte™ users ate less but did not get hungry sooner than non-SmartByte™ users.
• Excess body weight loss (the difference between ideal weight and actual weight) averaged 38.1% after 16 weeks among subjects who used the device as directed.

Over the past decade, many epidemiological and laboratory studies have linked rising overweight and obesity with rate of food intake.  See Science & Research for further information.

© 2017 Scientific Intake Limited Co.